Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine,Physiology,Internal Medicine
Reference10 articles.
1. Packer M, McMurray J, Massie BM, Caspi A, Charlon V, Cohen-Solal A, Kiowski W, Kostuk W, Krum H, Levine B, Rizzon P, Soler J, Swedberg K, Anderson S, Demets DL . Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail 2005; 11: 12–20.
2. Kalra PR, Moon JC, Coats AJ . Do results of the enable (endothelin antagonist bosentan for lowering cardiac events in heart failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol 2002; 85: 195–197.
3. Saito Y, Nakamura K, Akagi S, Sarashina T, Ejiri K, Miura A, Ogawa A, Matsubara H, Ito H . Epoprostenol sodium for treatment of pulmonary arterial hypertension. Vasc Health Risk Manag 2015; 11: 265–270.
4. Califf RM, Adams KF, McKenna WJ, Gheorghiade M, Uretsky BF, McNulty SE, Darius H, Schulman K, Zannad F, Handberg-Thurmond E, Harrell FE Jr, Wheeler W, Soler-Soler J, Swedberg K . A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The flolan international randomized survival trial (first). Am Heart J 1997; 134: 44–54.
5. Wu X, Yang T, Zhou Q, Li S, Huang L . Additional use of a phosphodiesterase 5 inhibitor in patients with pulmonary hypertension secondary to chronic systolic heart failure: A meta-analysis. Eur J Heart Fail 2014; 16: 444–453.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献